Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Polarean Imaging Temettü

Temettü kriter kontrolleri 0/6

Polarean Imaging şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	2.4%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-UK£0.0071
Temettü verim tahmini	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

We Think Shareholders Will Probably Be Generous With Polarean Imaging plc's (LON:POLX) CEO Compensation

Jul 07

Here's Why We're Watching Polarean Imaging's (LON:POLX) Cash Burn Situation

Jun 07

Insider Buying: The Polarean Imaging plc (LON:POLX) Independent Chairman Just Bought 6.6% More Shares

Mar 18

Polarean Imaging (LON:POLX) Is In A Good Position To Deliver On Growth Plans

Mar 09

Polarean Imaging (LON:POLX) Shareholders Have Enjoyed An Impressive 135% Share Price Gain

Feb 01

Should You Take Comfort From Insider Transactions At Polarean Imaging plc (LON:POLX)?

Dec 28

What Type Of Shareholders Own The Most Number of Polarean Imaging plc (LON:POLX) Shares?

Nov 30

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: POLX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: POLX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Polarean Imaging Piyasaya Karşı Temettü Getirisi

POLX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (POLX)	n/a
Pazarın Alt %25'i (GB)	2.1%
Pazarın En İyi %25'i (GB)	5.6%
Sektör Ortalaması (Medical Equipment)	2.4%
Analist tahmini (POLX) (3 yıla kadar)	n/a

Önemli Temettü: POLX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, POLX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: POLX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: POLX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Polarean Imaging Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Polarean Imaging plc Appoints Chase Hall, M.D., as Chief Medical Advisor

Polarean Imaging plc to Report First Half, 2024 Results on Sep 04, 2024

Bastiaan Driehuys Steps Down from His Position on the Board of Polarean Imaging plc

Polarean Imaging plc Submits New Drug Application Supplement to the US Food and Drug Administration

Full year 2023 earnings released: US$0.055 loss per share (vs US$0.066 loss in FY 2022)

Polarean Imaging plc, Annual General Meeting, Jul 24, 2024

New major risk - Shareholder dilution

New minor risk - Financial data availability

Here's Why Polarean Imaging (LON:POLX) Must Use Its Cash Wisely

First half 2023 earnings released: US$0.035 loss per share (vs US$0.033 loss in 1H 2022)

Is Polarean Imaging (LON:POLX) In A Good Position To Invest In Growth?

Polarean Imaging plc to Report First Half, 2023 Results on Sep 07, 2023

Polarean Imaging plc to Report First Half, 2023 Results on Sep 07, 2023

New major risk - Share price stability

Polarean Receives Clearance for New MRI Chest Coil

Polarean Imaging plc Announces CEO Changes

Full year 2022 earnings released: US$0.066 loss per share (vs US$0.071 loss in FY 2021)

Polarean Imaging plc, Annual General Meeting, Jun 28, 2023

Polarean Imaging plc Announces First Clinical Scan Using XENOVIEW Conducted At Cincinnati Children’s Hospital Medical Center

Is Polarean Imaging (LON:POLX) In A Good Position To Invest In Growth?

Polarean Imaging plc Announces FDA Grants New Chemical Entity Designation for XENOVIEW

Polarean Imaging plc Announces U.S. Food and Drug Administration Grants Approval for its Drug Device Combination Product, XENOVIEW

Less than half of directors are independent

We're Keeping An Eye On Polarean Imaging's (LON:POLX) Cash Burn Rate

Polarean Imaging plc Announces Update on New Drug Application

First half 2022 earnings released: US$0.033 loss per share (vs US$0.026 loss in 1H 2021)

Polarean Imaging plc Appoints Marcella Ruddy as A Non-Executive Director

Polarean Imaging plc, Annual General Meeting, Jun 29, 2022

Full year 2021 earnings released: US$0.071 loss per share (vs US$0.044 loss in FY 2020)

Polarean Imaging plc to Report Fiscal Year 2021 Results on May 18, 2022

Polarean Imaging plc Announces Board and Committee Changes

Less than half of directors are independent

Polarean Imaging plc Announces New Drug Application Resubmission Update

Polarean Imaging plc Appoints Frank Maria Schulkes as Non-Executive Director

Polarean Imaging plc Announces Resubmission of New Drug Application

Polarean Imaging (LON:POLX) Is In A Good Position To Deliver On Growth Plans

Independent Chairman recently bought UK£80k worth of stock

First half 2021 earnings released: US$0.026 loss per share (vs US$0.023 loss in 1H 2020)

We Think Shareholders Will Probably Be Generous With Polarean Imaging plc's (LON:POLX) CEO Compensation

Here's Why We're Watching Polarean Imaging's (LON:POLX) Cash Burn Situation

Full year 2020 earnings released: US$0.044 loss per share (vs US$0.057 loss in FY 2019)

Insider Buying: The Polarean Imaging plc (LON:POLX) Independent Chairman Just Bought 6.6% More Shares

Polarean Imaging (LON:POLX) Is In A Good Position To Deliver On Growth Plans

Polarean Imaging plc Announces the Appointment of Charles Fremont Osborne Jr. to the Board

Polarean Imaging (LON:POLX) Shareholders Have Enjoyed An Impressive 135% Share Price Gain

Should You Take Comfort From Insider Transactions At Polarean Imaging plc (LON:POLX)?

Polarean Imaging plc Announces FDA Acceptance for the Filing of New Drug Application

New 90-day high: UK£0.80

What Type Of Shareholders Own The Most Number of Polarean Imaging plc (LON:POLX) Shares?

New 90-day high: UK£0.80

Polarean Imaging plc Receives Research Unit Order for A 9820 Xenon Polariser System from the University of Texas MD Anderson Cancer Center

New 90-day high: UK£0.49

Polarean Imaging plc Announces Submission of New Drug Application

First half earnings released

Polarean Imaging plc Completes the Installation of its Latest Research Unit Order for A 9820 Xenon Polariser System

New 90-day high: UK£0.47

New 90-day high - UK£0.36

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin